Zydus Cadila to propose 3 doses vaccine which could cost Rs 1900

zydus cadila
Zydus Cadila to propose 3 doses vaccine which could cost Rs 1900

There are talks taking place with the government of India and Zydus Cadila regarding the price of the COVID-19 vaccination ZyCov-D. The pharmaceutical company has suggested a cost of Rs 1,900 for the three-dose jab, which can be administered to over 12 years old.
The government is currently negotiating an increase in cost. A final determination will likely be made next week, people who are aware of the latest developments told PTI.
Zydus has offered an amount of Rs. One thousand nine hundred with tax included for the three-dose jab. “Negotiations are in progress. The company is being requested to review all aspects of the price for the vaccination. A final decision about the cost for the vaccination is expected to be taken by the end of this next week,” A source told.
Another source claimed that the ZyCoV-D vaccine has to be differently priced from Covaxin and Covishield because, in addition to having three doses, there is a needle-free injector for administering the vaccine, which is priced at around Rs 3000. The jet injector is utilized to administer up to 220 doses.
The vaccine will be administered on days zero, 28, and 56. According to reports, about three meetings have been held in the past in between Centre and the business The last one on Thursday.
In the meantime, the ministry is also waiting for the recommendations of the National Technical Advisory Group for Immunisation (NTAGI ) to introduce ZyCoV in the inoculation program and prioritizing beneficiaries with a focus on 12 to 18 yr old persons with multiple comorbidities. The NTAGI will issue the guidelines and protocol to introduce this vaccine as part of the COVID-19 immunization campaign, An official source told.
In terms of the cost of the vaccine and how it is purchased, Union Health Secretary Rajesh Bhushan declared that the government was talking to the makers at a press conference held on Thursday. “Since it is a three-dose vaccine that comes with an injection system that is needle-free that it could be priced differently as compared to the current vaccines that are used as part of the COVID vaccination program,” he said.
Zyvox D was the vaccine that received an emergency Use Authorization from the drug regulator on 20 August, which is the first time a vaccine has been approved that is available to those in the age group between 12-18 years old in addition to adults. The vaccines Covishield, Covaxin, and Sputnik V, are given only to people who are 18 years old. Unlike ZyCoV, they are two-dose vaccines.

Leave a Reply

Your email address will not be published.